sweelin®, a novel sweet protein, does not affect blood glucose and insulin levels - a double-blind, crossover, randomized study.

Abstract

A novel hyper-sweet protein, sweelin®, enables sugar reduction without compromising taste. This double-blind, randomized, crossover study evaluated the effect of sweelin® on blood glucose, insulin and GLP-1 levels compared to stevia and dextrose in healthy adults. In this study, subjects consumed sweelin® (0.051 g), stevia Reb-M (0.225 g) or dextrose (75 g) in beverages matched for sweetness levels. Blood samples were collected at baseline and during 120-min post consumption. Each participant (n = 19) consumed each of the three beverages in a randomized order. At every time point after consumption, as well as iAUC, glucose and insulin levels were significantly lower following sweelin® consumption compared to dextrose (p < 0.0001), and not different from stevia. Overall, the findings indicate that sweelin®, is well tolerated and does not increase blood glucose, insulin or GLP-1 levels in healthy individuals, and suggest that sweelin® may serve as a metabolically neutral alternative for individuals seeking to reduce sugar intake. This trial was registered at clinicaltrials.gov (identifier code: NCT06520293).